Blosozumab

BIOLOGICAL2 trials

Sponsors

Eli Lilly and Company

Conditions

Osteoporosis, Postmenopausal

Phase 1

A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants

CompletedNCT02109042

Eli Lilly and CompanyOsteoporosis, Postmenopausal

Start: 2014-04-30End: 2014-07-31Updated: 2018-07-16

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

TerminatedNCT02337387

Eli Lilly and CompanyOsteoporosis, Postmenopausal

Start: 2015-01-31End: 2015-03-31Updated: 2019-01-22